RVMD

161.7901.48%
KM

Kevan M. Shokat

Co-Founder and Member of Clinical & Scientific Advisory Board

Dr. Kevan M. Shokat, Ph.D. is Chair of Scientific Advisory Council of Cold Spring Harbor Laboratory Inc. Dr. Shokat is an investigator with the Howard Hughes Medical Institute, a position he has held since 2005. He serves as a Professor and Vice-Chairman in the Department of Cellular and Molecular Pharmacology at the University of California, San Francisco and as Professor of Chemistry at the University of California, Berkeley. Dr. Shokat is Co-Founder of Intellikine LLC and also serves as Chairman of its Scientific Advisory Board and as a Board Observer. He is Co-Founder of eFFECTOR Therapeutics, Inc. and also serves as its Member of Clinical & Scientific Advisory Board. He is academic Co-Founder of REVOLUTION Medicines, Inc. and also serves as a Member of its Scientific Advisory Board since December 13, 2016. He is Scientific Co-Founder of Nested Therapeutics, Inc. and also serves as a Member of its Scientific Advisory Board. He is Co-Founder of Rezo Therapeutics, Inc., Scientific Co-Founder of CGI Pharmaceuticals, Inc. and Co-Founder of Araxes, Wellspring Biosciences and Mitokinin. His other current roles include serving as Director of Rezo Therapeutics Inc., Chairman of the Scientific Advisory Board of Kura Oncology, Inc., Chairman of the Scientific Advisory Board of Meryx Inc., Chairman of the Scientific Advisory Board of Turning Point Therapeutics, Inc. since August 2020 and Chairman of the Scientific Advisory Board at Kumquat Biosciences Inc. He serves as a Scientific Advisory Board Member at Vicinitas Therapeutics, Inc., as a Member of the Scientific Advisory Board at BridGene Biosciences, Inc., as a Member of the Scientific Advisory Board at Totus Medicines Inc. since May 2022, as a Member of the Scientific Advisory Board at Erasca, Inc., as a Member of the Scientific Advisory Board at Blade Therapeutics, Inc. and as a Member of the Scientific Advisory Board at Petra Pharma Corporation since July 27, 2017. He also serves as a Member of the Scientific Resource Board at Genentech, Inc., as a Scientific Advisor of TaconicArtemis GmbH, as a Member of the Scientific Advisory Board of BioSeek Inc. and as a Member of the Scientific Advisory Board of Thios Pharmaceuticals, Inc. Previously, Dr. Shokat was Co-Founder at Vevo Therapeutics, Inc. until 2025 and Co-Founder of Tahoe Therapeutics Inc. until 2025. He served as a Member of the Scientific Advisory Board at BioTheryX, Inc. from April 2021 to 2025. He served as Member of Scientific Advisory Board for Denali Therapeutics Inc. from May 2023 and also served as Member of Scientific Advisory Board at the company until 2023. He served as Member of Scientific Advisory Board at Ikena Oncology, Inc. from November 2020. He was a Co-Founder of Cellular Genomics, Inc. His prior advisory roles include serving as a Scientific Advisor of 5AM Venture Management, LLC and as a Member of the Scientific Advisory Board at St. Jude Children's Research Hospital, Inc., Catalyst Biosciences, Inc., CGI Pharmaceuticals, Inc. and Receptos, Inc. He began his independent research career at Princeton University, where he served as an Assistant Professor of Chemistry and Molecular Biology. Dr. Shokat is an innovator in the development of chemical methods for investigating cellular signal transduction pathways, with a particular focus on protein and lipid kinases. He has received numerous awards, including the Eli Lilly Award and has been named a Fellow of the Pew Foundation, Searle Foundation, Sloan Foundation, Glaxo-Wellcome Foundation and the Cotrell Foundation. In 2010, he was inducted into the National Academy of Sciences, followed by the National Academy of Medicine and the American Academy of Arts and Sciences in 2011. He completed Post-Doctoral work in cellular immunology at Stanford University in 1994. He holds a Ph.D. in Organic Chemistry from The University of California, Berkeley, which he received in 1991 and both a B.S. in Chemistry and a B.A. in Chemistry from Reed College, which he received in 1986.

Positions